<?xml version='1.0' encoding='utf-8'?>
<document id="31411766"><sentence text="In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants." /><sentence text="As an alternative to vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) are increasingly prescribed in combination with riociguat in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)"><entity charOffset="21-30" id="DDI-PubMed.31411766.s2.e0" text="vitamin K" /></sentence><sentence text=" Pharmacokinetics of riociguat and DOACs are influenced by efflux transporters, such as P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP)" /><sentence text=" This work aimed to assess P-gp and BCRP-mediated drug-drug interactions of riociguat with DOACs using in vitro models" /><sentence text=" Bidirectional permeabilities of apixaban and rivaroxaban were investigated across MDCK-MDR1 and MDCK-BCRP models, in the absence and in the presence of increasing concentrations of riociguat (0"><entity charOffset="33-41" id="DDI-PubMed.31411766.s5.e0" text="apixaban" /><entity charOffset="46-57" id="DDI-PubMed.31411766.s5.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.31411766.s5.e0" e2="DDI-PubMed.31411766.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31411766.s5.e0" e2="DDI-PubMed.31411766.s5.e1" /></sentence><sentence text="5-100 μm)" /><sentence text=" Calculated efflux ratios were subsequently used to determine riociguat inhibition percentages and half maximal inhibitory concentration (IC50)" /><sentence text=" P-gp-mediated efflux of apixaban and rivaroxaban was inhibited by 8% and 21%, respectively, in the presence of 100 μm riociguat"><entity charOffset="25-33" id="DDI-PubMed.31411766.s8.e0" text="apixaban" /><entity charOffset="38-49" id="DDI-PubMed.31411766.s8.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.31411766.s8.e0" e2="DDI-PubMed.31411766.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31411766.s8.e0" e2="DDI-PubMed.31411766.s8.e1" /></sentence><sentence text=" BCRP-mediated transport of apixaban and rivaroxaban was inhibited by 36% and 77%, respectively"><entity charOffset="28-36" id="DDI-PubMed.31411766.s9.e0" text="apixaban" /><entity charOffset="41-52" id="DDI-PubMed.31411766.s9.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.31411766.s9.e0" e2="DDI-PubMed.31411766.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31411766.s9.e0" e2="DDI-PubMed.31411766.s9.e1" /></sentence><sentence text=" IC50s of riociguat on MDCK-MDR1 and MDCK-BCRP models were higher than 100 μm for apixaban and higher than 100 μm and 46"><entity charOffset="82-90" id="DDI-PubMed.31411766.s10.e0" text="apixaban" /></sentence><sentence text="5 μm for rivaroxaban, respectively"><entity charOffset="9-20" id="DDI-PubMed.31411766.s11.e0" text="rivaroxaban" /></sentence><sentence text=" This work showed an in vitro inhibition of BCRP-mediated DOACs transport by riociguat" /><sentence text=" In vivo studies may be required to determine the clinical relevance of these transporter-mediated interactions" /><sentence text="" /></document>